Abstract
Current prostate cancer (PCa) diagnosis is based in the serum prostate-specific antigen biomarker and digital rectal examination. However, these methods are limited by a low predictive value (24–37 %) and a high risk of mistaken results. During last years, new promising biomarkers such as Prostate Cancer Antigen 3 (PCA-3) and TMPRSS2-ETS fusion genes have been evaluated for their clinical use. However, the search of new biomarkers that could be used for PCa diagnosis and prognosis is still needed. Recent studies have demonstrated that the aberrant expression of microRNAs (miRNAs), small non-coding RNAs that negatively regulate gene expression, is related with the development of several cancers, including PCa. Since miRNAs serve as phenotypic signatures of different cancers, they appear as potential diagnostic, prognostic and therapeutic tools. Here, we review the current knowledge of miRNA expression patterns in PCa and their role in PCa prognosis and therapeutics.
Similar content being viewed by others
References
Fernández-Serra A, Rubio-Briones J, García-Casado Z, Solsona E, López-Guerrero JA (2011) Cáncer de próstata: la revolución de los genes de fusión. Act Urol Esp 35:420–428
Bunting PS (2002) Screening for prostate cancer with prostate-specific antigen: beware the biases. Clin Chim Acta 315:71–97
Thompson IM, Ankerst DP, Chi C, Goodman PJ, Tangen CM et al (2006) Assessing prostate cancer risk: results from the prostate cancer prevention trial. Cancer 78229:529–534
Stamey TA, Yang N, Hay AR, McNeal JE, Freiha FS et al (1987) Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. N Engl J Med 317:909–916
Tricoli JV, Schoenfeldt M, Conley BA (2004) Detection of prostate cancer and predicting progression: current and future diagnostic markers. Clin Cancer Res 10:3943–3953
Schröder FH, van der Cruijsen-Koeter I, de Koning HJ, Vis AN, Hoedemaeker RF et al (2000) Prostate cancer detection at low prostate specific antigen. J Urol 163:806–812
Rubio-Briones J, Fernández-Serra A, Ramírez M, Rubio L, Collado A et al (2011) Resultados del uso expandido del PCA3 score en una población española con sospecha de cáncer de próstata. Act Urol Esp 35:589–596
Salagierski M, Schalken JA (2012) Molecular diagnosis of prostate cancer: PCA3 and TMPRSS2:ERG gene fusion. J Urol 187:795–801
Ryan BM, Robles AI, Harris CC (2010) Genetic variation in microRNA. Nat Rev Cancer 10:389–402
Pang Y, Young CYF, Yuan H (2010) MicroRNAs and prostate cancer. Acta Biochim Biophys Hung 42:363–369
Calin GA, Dumitru CD, Shimizu M, Bichi R, Zupo S et al (2002) Frequent deletions and down-regulation of micro-RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. PNAS 99:13–18
Porkka KP, Pfeiffer MJ, Waltering KK, Vessella RL (2007) MicroRNA expression profiling in prostate cancer. Cancer Res 67:6130–6135
Saini S, Majid S, Dahiya R (2010) Diet, microRNAs and prostate cancer. Pharm Res 27:1014–1026
Esquela-Kerscher A, Slack FJ (2006) Oncomirs-microRNAs with a role in cancer. Nat Rev Cancer 6:259–269
Karube Y, Tanaka H, Osada H, Tomida S, Tatematsu Y et al (2005) Reduced expression of Dicer associated with poor prognosis in lung cancer patients. Cancer Sci 96:111–115
Cimmino A, Calin GA, Fabbri M, Iorio MV, Ferracin M et al (2005) miR-15 and miR-16 induce apoptosis by targeting BCL2. PNAS 102:13944–13949
Volinia S, Calin GA, Liu C-gong, Ambs S, Cimmino A et al (2005) A microRNA expression signature of human solid tumors defines cancer gene targets. PNAS 103:2257–2261
Lu J, Getz G, Miska EA, Alvarez-saavedra E, Lamb J et al (2005) MicroRNA expression profiles classify human cancers. Nature 435:834–838
Johnson SM, Grosshans H, Shingara J, Byrom M, Jarvis R et al (2005) RAS is regulated by the let-7 MicroRNA family. Cell 120:635–647
Michael MZ, Connor SMO, Pellekaan NGVH, Young GP, James RJ (2003) Reduced accumulation of specific microRNAs in colorectal neoplasia. Mol Cancer Res 1:882–891
Ciafrè SA, Galardi S, Mangiola A, Ferracin M, Liu C-G et al (2005) Extensive modulation of a set of microRNAs in primary glioblastoma. Biochem Biophys Res Commun 334:1351–1358
Chan JA, Krichevsky AM, Kosik KS (2005) MicroRNA-21 is an antiapoptotic factor in human glioblastoma cells. Cancer Res 65:6029–6033
Eis PS, Tam W, Sun L, Chadburn A, Li Z et al (2005) Accumulation of miR-155 and BIC RNA in human B cell lymphomas. Synthesis 102:3627–3632
Murakami Y, Yasuda T, Saigo K, Urashima T, Toyoda H et al (2006) Comprehensive analysis of microRNA expression patterns in hepatocellular carcinoma and non-tumorous tissues. Oncogene 25(17):2537–2545
Zhang B, Pan X, Cobb GP, Anderson TA (2007) microRNAs as oncogenes and tumor suppressors. Dev Biol 302:1–12
Mitchell PS, Parkin RK, Kroh EM, Fritz BR, Wyman SK et al (2008) Circulating microRNAs as stable blood-based markers for cancer detection. PNAS 105:10513–10518
Lodes MJ, Caraballo M, Suciu D, Munro S, Kumar A et al (2009) Detection of cancer with serum miRNAs on an oligonucleotide microarray. PLoS One 4:e6229
Weber JA, Baxter DH, Zhang S, Huang DY, Huang KH et al (2010) The microRNA spectrum in 12 body fluids. Clin Chem 56:1733–1741
X-bao Shi, Xue L, Yang J, Ma A-H, Zhao J et al (2007) An androgen-regulated miRNA suppresses Bak1 expression and induces androgen-independent growth of prostate cancer cells. PNAS 104:19983–19988
Ribas J, Ni X, Haffner M, Wentzel EA, Salmasi AH et al (2009) miR-21: an androgen receptor-regulated microRNA that promotes hormone-dependent and hormone-independent prostate cancer growth. Cancer Res 69:7165–7169
Catto JWF, Alcaraz A, Bjartell AS, Vere RD, Evans CP et al (2011) MicroRNA in prostate, bladder, and kidney cancer: a systematic review. Eur Urol 59:671–681
Epis MR, Giles KM, Barker A, Kendrick TS, Leedman PJ (2009) miR-331-3p regulates ERBB-2 expression and androgen receptor signaling in prostate cancer. J Biol Chem 284:24696–24704
White RW, Vinall RL, Tepper CG, Shi X-B (2010) MicroRNAs and their potential for translation in prostate cancer. Urol Oncol 27:307–311
Brase JC, Johannes M, Schlomm T, Fälth M, Haese A et al (2011) Circulating miRNAs are correlated with tumor progression in prostate cancer. Int J Cancer 128:608–616
Zaman MS, Chen Y, Deng G, Shahryari V, Suh SO et al (2010) The functional significance of microRNA-145 in prostate cancer. Br J Cancer 103:256–264
Watahiki A, Wang Y, Morris J, Dennis K, Dwyer HMO et al (2011) MicroRNAs associated with metastatic prostate cancer. PLoS One 6:e24950
Szczyrba J, Löprich E, Wach S (2010) The microRNA profile of prostate carcinoma obtained by deep sequencing. Mol Cancer Res 8:529–538
Peng X, Guo W, Liu T, Wang X, Tu X et al (2011) Identification of miRs-143 and -145 that is associated with bone metastasis of prostate cancer and involved in the regulation of EMT. PLoS One 6:e20341
Ambs S, Prueitt RL, Yi M, Hudson RS, Howe TM et al (2008) Genomic profiling of microRNA and messenger RNA reveals deregulated microRNA expression in prostate cancer. Cancer Res 68:6162–6170
Tong AW, Fulgham P, Jay C, Chen P, Khalil I et al (2009) MicroRNA profile analysis of human prostate cancers. Cancer Gene Ther 16:206–216
Saini S, Majid S, Yamamura S (2011) Regulatory role of mir-203 in prostate cancer progression and metastasis. Clin Cancer Res 17:5287–5298
Wang L, Tang H, Thayanithy V, Subramanian S, Oberg AL et al (2010) Gene networks and microRNAs implicated in aggressive prostate cancer. Cancer Res 69:9490–9497
Bex A (2011) Translating translational repression: evolving possibilities in uro-oncology. Eur Urol 59:682–683
Tomlins SA, Rhodes DR, Perner S, Dhanasekaran SM, Mehra R et al (2005) Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 310:644–648
Rubio-Briones J, Fernández-Serra A, Calatrava A, García-Casado Z, Rubio L et al (2010) Clinical implications of TMPRSS2-ERG gene fusion expression in patients with prostate cancer treated with radical prostatectomy. J Urol 183:2054–2061
Gordanpour A, Stanimirovic A, Nam RK, Moreno CS, Sherman C et al (2011) miR-221 Is down-regulated in TMPRSS2:ERG fusion-positive prostate cancer. Anticancer Res 31:403–410
Kota J, Chivukula RR, O’Donnell KA, Wentzel EA, Montgomery CL et al (2009) Therapeutic microRNA delivery suppresses tumorigenesis in a murine liver cancer model. Cell 137:1005–1017
Bhardwaj A, Singh S, Singh AP (2010) MicroRNA-based cancer therapeutics: big hope from small RNAs. Mol Cell Pharmacol 2:213–219
Si M-L, Zhu S, Wu H, Lu Z, Wu F et al (2007) miR-21-mediated tumor growth. Oncogene 26:2799–2803
Krützfeldt J, Rajewsky N, Braich R, Rajeev KG, Tuschl T et al (2005) Silencing of microRNAs in vivo with “antagomirs”. Nature 438:685–689
Ebert MS, Neilson JR, Sharp PA (2007) MicroRNA sponges: competitive inhibitors of small RNAs in mammalian cells. Nat Methods 4:721–726
Gumireddy K, Young DD, Xiong X, Hogenesch JB, Huang Q et al (2008) Small-molecule inhibitors of microrna miR-21 function. Angew Chem Int Ed Engl 47:7482–7484
Garzon R, Pichiorri F, Palumbo T, Iuliano R, Cimmino A et al (2006) MicroRNA fingerprints during human megakaryocytopoiesis. PNAS 103:5078–5083
Poliseno L, Salmena L, Riccardi L, Fornari A, Song MS et al (2010) Identification of the miR-106b~25 microRNA cluster as a proto-oncogenic PTEN-targeting intron that cooperates with its host gene MCM7 in transformation. Sci Signal 3:ra29
Schaefer A, Jung M, Mollenkopf H-J, Wagner I, Stephan C et al (2010) Diagnostic and prognostic implications of microRNA profiling in prostate carcinoma. Int J Cancer 1176:1166–1176
Bhatnagar N, Li X, Padi SKR, Zhang Q, Tang M-S et al (2010) Downregulation of miR-205 and miR-31 confers resistance to chemotherapy-induced apoptosis in prostate cancer cells. Cell Death Dis 9:e105
Hermeking H (2009) The miR-34 family in cancer and apoptosis. Cell Death Differ 17:193–199
Guttilla IK, White BA (2009) Coordinate regulation of FOXO1 by miR-27a, miR-96, and miR-182 in breast cancer cells. J Biol Chem 284:23204–23216
Mihelich BL, Khramtsova EA, Arva N, Vaishnav A, Johnson DN et al (2011) miR-183-96-182 cluster is overexpressed in prostate tissue and regulates zinc homeostasis in prostate cells. J Biol Chem 286:44503–44511
Shi X-B, Xue L, Ma A-H, Tepper CG, Kung H-J et al (2011) miR-125b promotes growth of prostate cancer xenograft tumor through targeting pro-apoptotic genes. Prostate 71:538–549
Kiriakidou M, Nelson PT, Kouranov A, Fitziev P, Bouyioukos C et al (2004) A combined computational-experimental approach predicts human microRNA targets. Genes Dev 18:1165–1178
Fujita Y, Kojima K, Ohhashi R, Hamada N, Nozawa Y et al (2010) MiR-148a attenuates paclitaxel resistance of hormone-refractory, drug-resistant prostate cancer PC3 cells by regulating MSK1 expression. J Biol Chem 285:19076–19084
Murata T, Takayama K, Katayama S, Urano T, Horie-Inoue K et al (2010) miR-148a is an androgen-responsive microRNA that promotes LNCaP prostate cell growth by repressing its target CAND1 expression. Prostate Cancer Prostatic Dis 13:356–361
Prueitt RL, Yi M, Hudson RS, Wallace TA, Howe TM et al (2008) Expression of microRNAs and protein-coding genes associated with perineural invasion in prostate cancer. Prostate 68:1152–1164
Schnall-Levin M, Rissland OS, Johnston W, Perrimon N, Bartel DP et al (2011) Unusually effective microRNA targeting within repeat-rich coding regions of mammalian mRNAs. Genome Res 21:1395–1403
Moskwa P, Buffa FM, Pan Y, Panchakshari R, Gottipati P et al (2011) miR-182-mediated downregulation of BRCA1 impacts DNA repair and sensitivity to PARP inhibitors. Mol Cell 41:210–220
Barron N, Keenan J, Gammell P, Martinez VG, Freeman A et al (2011) Biochemical relapse following radical prostatectomy and miR-200a levels in prostate cancer. Prostate. doi:10.1002/pros.22469
Su J, Zhang A, Shi Z, Ma F, Pu P et al (2011) MicroRNA-200a suppresses the Wnt/β-catenin signaling pathway by interacting with β-catenin. Int J Oncol 40:1162–1170
Eades G, Yao Y, Yang M, Zhang Y, Chumsri S et al (2011) MiR-200a regulates SIRT1 and EMT-like transformation in mammary epithelial cells. J Biol Chem 286:25992–26002
Szczyrba J, Nolte E, Wach S, Kremmer E, Stöhr R et al (2011) Downregulation of Sec23A protein by miRNA-375 in prostate carcinoma. Mol Cancer Res 9:791–800
Vallejo DM, Caparros E (2011) Targeting Notch signalling by the conserved miR-8/200 microRNA family in development and cancer cells. EMBO J 30:756–769
Chan YC, Banerjee J, Choi SY, Sen CK (2012) miR-210: the master hypoxamir. Microcirculation 19:215–223
Derfoul A, Juan AH, Difilippantonio MJ, Palanisamy N, Ried T et al (2011) Decreased microRNA-214 levels in breast cancer cells coincides with increased cell proliferation, invasion and accumulation of the Polycomb Ezh2 methyltransferase. Carcinogenesis 32:1607–1614
Liu J, Luo X-J, Xiong A-W, Zhang Z-D, Yue S et al (2010) MicroRNA-214 promotes myogenic differentiation by facilitating exit from mitosis via down-regulation of proto-oncogene N-ras. J Biol Chem 285:26599–26607
Yang H, Kong W, He L, Zhao J-J, O’Donnell JD et al (2008) MicroRNA expression profiling in human ovarian cancer: miR-214 induces cell survival and cisplatin resistance by targeting PTEN. Cancer Res 68:425–433
Leite KRM, Sousa-Canavez JM, Reis ST, Tomiyama AH, Camara-Lopes LH et al (2011) Change in expression of miR-let7c, miR-100, and miR-218 from high grade localized prostate cancer to metastasis. Urol Oncol 29:265–269
Wei J-J, Wu X, Peng Y, Shi G, Basturk O et al (2011) Regulation of HMGA1 expression by microRNA-296 affects prostate cancer growth and invasion. Clin Cancer Res 17:1297–1305
Tang J-T, Wang J-L, Du W, Hong J, Zhao S-L et al (2011) MicroRNA 345, a methylation-sensitive microRNA is involved in cell proliferation and invasion in human colorectal cancer. Carcinogenesis 32:1207–1215
Josson S, Sung S-Y, Lao K, Chung LWK, Johnstone PAS (2008) Radiation modulation of microRNA in prostate cancer cell lines. Prostate 68:1599–1606
Jia W, Eneh JO, Ratnaparkhe S, Altman MK, Murph MM (2011) MicroRNA-30c-2* expressed in ovarian cancer cells suppresses growth factor-induced cellular proliferation and downregulates the oncogene BCL9. Mol Cancer Res 9:1732–1745
Zhou H, Xu X, Xun Q, Yu D, Ling J et al (2012) microRNA-30c negatively regulates endometrial cancer cells by targeting metastasis-associated gene-1. Oncol Rep 27:807–812
Jiang J, Lee EJ, Gusev Y, Schmittgen TD (2005) Real-time expression profiling of microRNA precursors in human cancer cell lines. Nucleic Acids Res 33:5394–5403
Scott GK, Goga A, Bhaumik D, Berger CE, Sullivan CS et al (2007) Coordinate suppression of ERBB2 and ERBB3 by enforced expression of micro-RNA miR-125a or miR-125b. J Biol Chem 282:1479–1486
Lin Y, Wu J, Chen H, Mao Y, Liu Y et al (2012) Cyclin-dependent kinase 4 is a novel target in micoRNA-195-mediated cell cycle arrest in bladder cancer cells. FEBS Lett 586:442–447
Fei X, Qi M, Wu B, Song Y, Wang Y et al (2012) MicroRNA-195-5p suppresses glucose uptake and proliferation of human bladder cancer T24 cells by regulating GLUT3 expression. FEBS Lett 586:392–397
He J-F, Luo Y-M, Wan X-H, Jiang D (2011) Biogenesis of miRNA-195 and its role in biogenesis, the cell cycle, and apoptosis. J Biochem Mol Toxicol 25:404–408
Galardi S, Mercatelli N, Giorda E, Massalini S, Frajese GV et al (2007) miR-221 and miR-222 expression affects the proliferation potential of human prostate carcinoma cell lines by targeting p27kip1*. J Biol Chem 282:23716–23724
Spahn M, Kneitz S, Scholz C-J, Stenger N, Rüdiger T et al (2010) Expression of microRNA-221 is progressively reduced in aggressive prostate cancer and metastasis and predicts clinical recurrence. Int J Cancer 127:394–403
Zhang J, Zhang H, Liu J, Tu X, Zang Y et al (2012) miR-30 inhibits TGF-β1-induced epithelial-to-mesenchymal transition in hepatocyte by targeting Snail1. Biochem Biophys Res Commun 417:1100–1105
Kojima S, Chiyomaru T, Kawakami K, Yoshino H, Enokida H et al (2011) Tumour suppressors miR-1 and miR-133a target the oncogenic function of purine nucleoside phosphorylase (PNP) in prostate cancer. Br J Cancer 106:405–413
Giles KM, Barker A, Zhang PM, Epis MR, Leedman PJ (2011) MicroRNA regulation of growth factor receptor signaling in human cancer cells. Methods Mol Biol 676:147–163
Takeshita F, Patrawala L, Osaki M, Takahashi R-U, Yamamoto Y et al (2010) Systemic delivery of synthetic microRNA-16 inhibits the growth of metastatic prostate tumors via downregulation of multiple cell-cycle genes. Mol Ther 18:181–187
Gao P, Tchernyshyov I, Chang T-C, Lee Y-S, Kita K et al (2009) c-Myc suppression of miR-23 enhances mitochondrial glutaminase and glutamine metabolism. Nature 458:762–765
Fukuda Y, Kawasaki H, Taira K (2005) Exploration of human miRNA target genes in neuronal differentiation. Nucleic Acid Symp Ser 49:341–342
Kapinas K, Kessler C, Ricks T, Gronowicz G, Delany AM (2010) miR-29 modulates Wnt signaling in human osteoblasts through a positive feedback loop. J Biol Chem 285:25221–25231
Xu H, Cheung IY, Guo H-F, Cheung N-KV (2009) MicroRNA miR-29 modulates expression of immunoinhibitory molecule B7–H3: potential implications for immune based therapy of human solid tumors. Cancer Res 69:6275–6281
Fujita Y, Kojima K, Hamada N, Ohhashi R, Akao Y et al (2008) Effects of miR-34a on cell growth and chemoresistance in prostate cancer PC3 cells. Biochem Biophys Res Commun 377:114–119
Kojima K, Fujita Y, Nozawa Y, Deguchi T, Ito M (2010) MiR-34a attenuates paclitaxel-resistance of hormone-refractory prostate cancer PC3 cells through direct and indirect mechanisms. Prostate 70:1501–1512
Tsuchida A, Ohno S, Wu W, Borjigin N, Fujita K et al (2011) miR-92 is a key oncogenic component of the miR-17-92 cluster in colon cancer. Cancer Sci 102:2264–2271
Sun D, Lee YS, Malhotra A, Kim HK, Matecic M et al (2011) miR-99 family of microRNAs suppresses the expression of prostate-specific antigen and prostate cancer cell proliferation. Cancer Res 71:1313–1324
Varambally S, Cao Q, Mani R-S, Shankar S, Wang X et al (2008) Genomic loss of microRNA-101 leads to overexpression of histone methyltransferase EZH2 in cancer. Science 322:1695–1699
Wang W-X, Kyprianou N, Wang X, Nelson PT (2010) Dysregulation of the mitogen granulin in human cancer through the miR-15/107 microRNA gene group. Cancer Res 70:9137–9142
Crawford M, Brawner E, Batte K, Yu L, Hunter MG et al (2008) MicroRNA-126 inhibits invasion in non-small cell lung carcinoma cell lines. Biochem Biophys Res Commun 373:607–612
Fish JE, Santoro MM, Morton SU, Yu S, Yeh R-F et al (2008) miR-126 regulates angiogenic signaling and vascular integrity. Dev Cell 15:272–284
Musiyenko A, Bitko V, Barik S (2008) Ectopic expression of miR-126*, an intronic product of the vascular endothelial EGF-like 7 gene, regulates prostein translation and invasiveness of prostate cancer LNCaP cells. J Mol Med 86:313–322
Evangelisti C, Florian MC, Massimi I, Dominici C, Giannini G et al (2009) MiR-128 up-regulation inhibits Reelin and DCX expression and reduces neuroblastoma cell motility and invasiveness. FASEB J 23:4276–4287
Khan AP, Poisson LM, Bhat VB, Fermin D, Zhao R et al (2010) Quantitative proteomic profiling of prostate cancer reveals a role for miR-128 in prostate cancer. Mol Cell Proteomics 9:298–312
Clapé C, Fritz V, Henriquet C, Apparailly F, Fernandez PL et al (2009) miR-143 interferes with ERK5 signaling, and abrogates prostate cancer progression in mice. PloS One 4:e7542
Xu B, Niu X, Zhang X, Tao J, Wu D et al (2011) miR-143 decreases prostate cancer cells proliferation and migration and enhances their sensitivity to docetaxel through suppression of KRAS. Mol Cell Biochem 350:207–213
Chen Z, Zeng H, Guo Y, Liu P, Pan H et al (2010) miRNA-145 inhibits non-small cell lung cancer cell proliferation by targeting c-Myc. J Exp Clin Cancer Res 29:151
Ozen M, Creighton CJ, Ozdemir M, Ittmann M (2008) Widespread deregulation of microRNA expression in human prostate cancer. Oncogene 27:1788–1793
S-lung L, Chiang A, Chang D, Ying S-Y (2008) Loss of mir-146a function in hormone-refractory prostate cancer. RNA 14:417–424
Gandellini P, Folini M, Longoni N, Colecchia M, Salvioni R et al (2009) miR-205 exerts tumor-suppressive functions in human prostate cancer through down-regulation of protein kinase Cε. Cancer Res 69:2287–2295
Majid S, Dar AA, Saini S, Yamamura S, Hirata H et al (2010) MicroRNA-205-directed transcriptional activation of tumor suppressor genes in prostate cancer. Cancer 116:5637–5649
Fazi F, Rosa A, Fatica A, Gelmetti V, De Marchis ML et al (2005) A minicircuitry comprised of microRNA-223 and transcription factors NFI-A and C/EBPalpha regulates human granulopoiesis. Cell 123:819–831
Shi W, Gerster K, Alajez NM, Tsang J, Waldron L et al (2011) MicroRNA-301 mediates proliferation and invasion in human breast cancer. Cancer Res 71:2926–2937
Bronisz A, Godlewski J, Wallace JA, Merchant AS, Nowicki MO et al (2011) Reprogramming of the tumour microenvironment by stromal PTEN-regulated miR-320. Nat Cell Biol 14:159–167
Lee K-H, Chen Y-L, Yeh S-D, Hsiao M, Lin J-T et al (2009) MicroRNA-330 acts as tumor suppressor and induces apoptosis of prostate cancer cells through E2F1-mediated suppression of Akt phosphorylation. Oncogene 28:3360–3370
Noonan EJ, Place RF, Pookot D, Basak S, Whitson JM et al (2009) miR-449a targets HDAC-1 and induces growth arrest in prostate cancer. Oncogene 28:1714–1724
Acknowledgments
This study is supported by Grants FIS PI10/01206 and FI11/00505 from the Instituto de Salud Carlos III; and ACOMP12/029 from the Generalitat Valenciana.
Conflict of interest
None.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Casanova-Salas, I., Rubio-Briones, J., Fernández-Serra, A. et al. miRNAs as biomarkers in prostate cancer. Clin Transl Oncol 14, 803–811 (2012). https://doi.org/10.1007/s12094-012-0877-0
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12094-012-0877-0